RSV Vaccination Prevents Associated Hospitalization, Emergency Encounters
THURSDAY, Nov. 7, 2024 -- For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associated hospitalizations and emergency department encounters, according to a study published online Oct. 19 in The Lancet.
Amanda B. Payne, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues assessed the effectiveness of RSV vaccines against RSV-associated hospitalizations and emergency department encounters among adults aged 60 years or older who underwent virus testing from Oct. 1, 2023, to March 31, 2024.
The researchers found that vaccine effectiveness was 80 and 81 percent against RSV-associated hospitalizations and against RSV-associated critical illness among 28,271 hospitalizations for RSV-like illness among adults aged 60 years or older without immunocompromising conditions. Vaccine effectiveness was 73 percent against associated hospitalizations among 8,435 hospitalizations in adults with immunocompromising conditions. Vaccine effectiveness was 77 percent against RSV-associated emergency department encounters among 36,521 emergency department encounters for RSV-like illness among adults aged 60 years or older without an immunocompromising condition.
"These findings provide additional context regarding the benefit of respiratory syncytial virus vaccination among adults aged at least 60 years," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
29 Percent of Infants Immunized Against RSV in 2023 to 2024 Season
MONDAY, Aug. 25, 2025 -- Overall, 29 percent of infants born during October 2023 to March 2024 were immunized against respiratory syncytial virus (RSV) during the 2023 to 2024...
Nirsevimab Effective for Protecting Infants From RSV Lower Respiratory Tract Disease
WEDNESDAY, July 30, 2025 -- Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), according...
Seniors With RSV-Linked Hospitalization Have Increased Cardiovascular Outcomes
THURSDAY, July 24, 2025 -- In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.